Clinical Scorecard: Evaluating the Antitumor Effects of Tricyclic Medications: A Comparative Study of Chlorpromazine, Amitriptyline, and Imipramine

At a Glance

Key Highlights

• Chlorpromazine (CPZ) demonstrated the strongest antitumorigenic effects across breast cancer and neuroblastoma cell lines.
• Amitriptyline (AmiT) showed intermediate effects, while Imipramine (ImiP) had the weakest inhibition of cancer cell growth.
• All three drugs failed to inhibit tumor growth in melanoma (A375) xenografts.
• In wound-healing assays, all drugs impaired migration in breast cancer and neuroblastoma cells but not in melanoma cells.
• The study supports the potential repurposing of FDA-approved tricyclic drugs for cancer treatment.

Guideline-Based Recommendations

Diagnosis

• Evaluate cancer type and stage when considering tricyclic medications for treatment.

Management

• Consider chlorpromazine and amitriptyline for breast cancer and neuroblastoma treatment.

Monitoring & Follow-up

• Monitor tumor growth response in patients treated with tricyclic medications.

Risks

• Assess potential side effects of tricyclic medications in oncology patients.

Patient & Prescribing Data

Patients with breast cancer, neuroblastoma, and melanoma

Tricyclic medications may address both psychiatric comorbidities and cancer-related symptoms.

Clinical Best Practices

• Utilize comparative studies to evaluate the antitumorigenic properties of tricyclic drugs.
• Incorporate patient mental health considerations when prescribing tricyclic medications.

Related Resources & Content

• Kamgar-Dayhoff and Brelidze study
• Epidemiological study from Denmark